EA034644B1 - Применение cart19 для истощения нормальных b-клеток для индукции толерантности - Google Patents

Применение cart19 для истощения нормальных b-клеток для индукции толерантности Download PDF

Info

Publication number
EA034644B1
EA034644B1 EA201590209A EA201590209A EA034644B1 EA 034644 B1 EA034644 B1 EA 034644B1 EA 201590209 A EA201590209 A EA 201590209A EA 201590209 A EA201590209 A EA 201590209A EA 034644 B1 EA034644 B1 EA 034644B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
cell
car
cart19
genetically modified
Prior art date
Application number
EA201590209A
Other languages
English (en)
Russian (ru)
Other versions
EA201590209A1 (ru
Inventor
Брюс Л. Левин
Майкл Д. Кейлос
Карл Х. Джун
Original Assignee
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания filed Critical Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Publication of EA201590209A1 publication Critical patent/EA201590209A1/ru
Publication of EA034644B1 publication Critical patent/EA034644B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201590209A 2012-07-13 2013-07-12 Применение cart19 для истощения нормальных b-клеток для индукции толерантности EA034644B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261671508P 2012-07-13 2012-07-13
PCT/US2013/050293 WO2014012001A2 (en) 2012-07-13 2013-07-12 Use of cart19 to deplete normal b cells to induce tolerance

Publications (2)

Publication Number Publication Date
EA201590209A1 EA201590209A1 (ru) 2015-08-31
EA034644B1 true EA034644B1 (ru) 2020-03-02

Family

ID=49916701

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590209A EA034644B1 (ru) 2012-07-13 2013-07-12 Применение cart19 для истощения нормальных b-клеток для индукции толерантности
EA201992742A EA201992742A3 (ru) 2012-07-13 2013-07-12 Применение cart19 для истощения нормальных b-клеток для индукции толерантности

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201992742A EA201992742A3 (ru) 2012-07-13 2013-07-12 Применение cart19 для истощения нормальных b-клеток для индукции толерантности

Country Status (13)

Country Link
US (3) US20150290244A1 (enExample)
EP (1) EP2872184B1 (enExample)
JP (5) JP2015523386A (enExample)
KR (1) KR102216083B1 (enExample)
CN (2) CN120393001A (enExample)
AU (3) AU2013289984B2 (enExample)
BR (1) BR112015000657B1 (enExample)
CA (1) CA2876734A1 (enExample)
EA (2) EA034644B1 (enExample)
ES (1) ES2835232T3 (enExample)
IN (1) IN2015DN00139A (enExample)
MX (2) MX382772B (enExample)
WO (1) WO2014012001A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
IN2015DN00139A (enExample) * 2012-07-13 2015-06-12 Univ Pennsylvania
KR102685501B1 (ko) 2013-02-20 2024-07-17 노파르티스 아게 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
EP2958942B1 (en) 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
EP3623380B1 (en) 2013-03-15 2025-10-22 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
JP6779785B2 (ja) 2013-12-19 2020-11-04 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
SG10202109752XA (en) * 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
CN113046321A (zh) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
BR112017001242A2 (pt) 2014-07-21 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico a cd33
TWI718992B (zh) 2014-07-21 2021-02-21 瑞士商諾華公司 使用cll-1嵌合抗原受體治療癌症
EP3172237A2 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
WO2016028879A1 (en) * 2014-08-19 2016-02-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating immune response
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
MX2017003645A (es) 2014-09-17 2017-05-30 Novartis Ag Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
CN106973568B (zh) 2014-10-08 2021-07-23 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
IL253149B2 (en) * 2014-12-29 2023-11-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
IL254817B2 (en) 2015-04-08 2023-12-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
JP7114457B2 (ja) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP4545082A3 (en) 2015-05-06 2025-07-02 SNIPR Technologies Limited Altering microbial populations & modifying microbiota
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
EP3858388B1 (en) * 2015-09-28 2024-07-03 Regents of the University of Minnesota Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd
CA3001910A1 (en) * 2015-10-13 2017-04-20 Eureka Therapeutics, Inc. Antibody agents specific for human cd19 and uses thereof
MX2018006767A (es) 2015-12-04 2019-03-14 Novartis Ag Composiciones y metodos para oncologia inmunologica.
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
MX2018012539A (es) * 2016-04-15 2019-07-08 Univ Pennsylvania Composiciones y métodos de células t receptoras de aloantígeno quimérico.
CA3021027A1 (en) * 2016-04-15 2017-10-19 Novartis Ag Compositions and methods for selective expression of chimeric antigen receptors
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
BR112019001327A2 (pt) * 2016-07-29 2019-04-30 Juno Therapeutics Inc anticorpos anti-idiotípicos e métodos relacionados
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
JP2019536786A (ja) * 2016-11-30 2019-12-19 イントレキソン コーポレーション ステロイドの投与および免疫療法
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
BR112019018124A2 (pt) 2017-03-22 2020-04-07 Intellia Therapeutics Inc composições e métodos para imunooncologia
JP7585034B2 (ja) 2017-10-18 2024-11-18 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
US12539308B2 (en) 2018-01-08 2026-02-03 The Trustees Of The University Of Pennsylvania Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP3806962A1 (en) 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
JP2021532116A (ja) * 2018-07-23 2021-11-25 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
BR112021003818A2 (pt) 2018-08-31 2021-05-25 Yale University composição, composição farmacêutica e método para modificar o genoma de uma célula
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CN115151275A (zh) 2019-08-30 2022-10-04 耶鲁大学 用于向细胞递送核酸的组合物和方法
CA3163104A1 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
KR20220104217A (ko) 2019-11-26 2022-07-26 노파르티스 아게 Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
CN114269902B (zh) * 2019-12-27 2025-02-18 昭泰英基生物医药（香港）有限公司 一种工程化免疫杀伤细胞、其制备方法及应用
AU2021205502A1 (en) * 2020-01-10 2022-07-21 Coimmune, Inc. Methods of treating tumors
EP4204002A1 (en) 2020-08-31 2023-07-05 Yale University Compositions and methods for delivery of nucleic acids to cells
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN120897933A (zh) 2022-10-11 2025-11-04 耶鲁大学 使用细胞穿透性抗体的组合物和方法
WO2024119101A1 (en) 2022-12-01 2024-06-06 Yale University Stimuli-responsive traceless engineering platform for intracellular payload delivery
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148419A1 (en) * 2005-12-07 2009-06-11 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2011097477A1 (en) * 2010-02-04 2011-08-11 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
WO2012079000A1 (en) * 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041756A1 (en) * 2004-11-17 2010-02-18 Michael Lionel Selley method of modulating b cell functioning
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
WO2011059836A2 (en) * 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
CA2821080C (en) * 2010-12-14 2021-02-02 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
IN2015DN00139A (enExample) * 2012-07-13 2015-06-12 Univ Pennsylvania

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148419A1 (en) * 2005-12-07 2009-06-11 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2011097477A1 (en) * 2010-02-04 2011-08-11 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
WO2012079000A1 (en) * 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer

Also Published As

Publication number Publication date
JP2025129358A (ja) 2025-09-04
US20180271907A1 (en) 2018-09-27
WO2014012001A2 (en) 2014-01-16
CA2876734A1 (en) 2014-01-16
JP2022173331A (ja) 2022-11-18
AU2020200315B2 (en) 2021-11-04
IN2015DN00139A (enExample) 2015-06-12
EA201992742A2 (ru) 2020-09-30
AU2013289984A1 (en) 2015-01-22
MX2018009820A (es) 2022-08-24
EA201590209A1 (ru) 2015-08-31
ES2835232T3 (es) 2021-06-22
AU2020200315A1 (en) 2020-02-06
MX2015000433A (es) 2016-04-28
MX382772B (es) 2025-03-11
AU2018203756B2 (en) 2019-10-24
AU2013289984B2 (en) 2018-03-08
JP2015523386A (ja) 2015-08-13
BR112015000657A2 (pt) 2017-06-27
EP2872184A2 (en) 2015-05-20
EP2872184B1 (en) 2020-09-16
JP2020158541A (ja) 2020-10-01
US20240261328A1 (en) 2024-08-08
CN120393001A (zh) 2025-08-01
JP2018135363A (ja) 2018-08-30
KR20150030750A (ko) 2015-03-20
KR102216083B1 (ko) 2021-02-17
AU2018203756A1 (en) 2018-06-21
WO2014012001A3 (en) 2015-04-23
BR112015000657A8 (pt) 2018-01-16
BR112015000657B1 (pt) 2023-12-05
CN104884095A (zh) 2015-09-02
EA201992742A3 (ru) 2020-12-30
EP2872184A4 (en) 2016-03-30
US20150290244A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
US20240261328A1 (en) Use of cart19 to deplete normal b cells to induce tolerance
US20230013642A1 (en) Toxicity Management for Anti-Tumor Activity of CARs
EA046588B1 (ru) Применение cart19 для лечения или предотвращения реакции "трансплантат против хозяина" (gvhd)
HK40116181A (en) Toxicity management for anti-tumor activity of cars
HK40116181B (en) Toxicity management for anti-tumor activity of cars
HK40069741A (en) Toxicity management for anti-tumor activity of cars
HK40039113A (en) Toxicity management for anti-tumor activity of cars
HK1253365B (en) Toxicity management for anti-tumor activity of cars

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM